SCHEMBL5873973

SCHEMBL5873973

C=Cc1ccc2c(c1)NC(=O)/C2=C\Nc1ccc(CCO)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 1/20 0.34
PIM1 P11309 3/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
PIM3 Q86V86 2/20 0.33
PIM2 Q9P1W9 2/20 0.33
CSF1R P07333 1/20 0.33
PDGFRB P09619 2/20 0.32
FLT3 P36888 2/20 0.32
AURKB Q96GD4 2/20 0.32
AURKA O14965 1/20 0.32
PDGFRA P16234 1/20 0.32
KDR P35968 1/20 0.32
AURKC Q9UQB9 1/20 0.32
KIT P10721 1/20 0.32
FLT4 P35916 1/20 0.32
GSK3B P49841 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CRHBP P24387 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5419264 1.00 TGM2 (0.34) TGM2PIM1MAOAMAOBPIM3
SCHEMBL5419268 1.00 TGM2 (0.34) TGM2PIM1MAOAMAOBPIM3
SCHEMBL5873972 0.87 CHEK1 (0.37) TGM2MAOAMAOBCSF1RGSK3B
SCHEMBL5422747 0.84 TGM2 (0.43) TGM2PIM1MAOAMAOBPIM3
SCHEMBL5873845 0.84 TGM2 (0.43) TGM2PIM1MAOAMAOBPIM3
SCHEMBL5422752 0.84 TGM2 (0.43) TGM2PIM1MAOAMAOBPIM3
SCHEMBL5419163 0.83 CSF1R (0.39) TGM2CSF1RGSK3BHTTNPSR1
SCHEMBL5419164 0.83 CSF1R (0.39) TGM2CSF1RGSK3BHTTNPSR1
SCHEMBL4992126 0.81 ALDH1A1 (0.50) TGM2PDGFRBFLT3PDGFRAKDR
SCHEMBL4992130 0.81 ALDH1A1 (0.50) TGM2PDGFRBFLT3PDGFRAKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7129253-B2 Compounds SMITHKLINE BEECHAM CORPORATION (US) 2006-10-31 US disclosed
US-7105529-B2 Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects SMITHKLINE BEECHAM CORPORATION (US) 2006-09-12 US disclosed
US-6818632-B2 3-(anilinomethylene)oxindoles SMITHKLINE BEECHAM CORPORATION 2004-11-16 US disclosed
US-20040191210-A1 Compounds GLENNON KIMBERLEY CAROLINE (US) 2004-09-30 US disclosed
US-20030069430-A1 Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects SMITHKLINE BEECHAM CORPORATION 2003-04-10 US disclosed
US-6498176-B1 INHIBITING TUMOR GROWTH VIA INHIBITION OF TUMOR-RELATED ANGIOGENESIS SMITHKLINEBEECHAM CORPORATION 2002-12-24 US disclosed
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia GLENNON KIMBERLEY CAROLINE (US) 2002-07-25 US disclosed
US-6369086-B1 Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2002-04-09 US disclosed
US-6350747-B1 PROTEIN SERINE/THREONINE KINASE AND PROTEIN TYROSINE KINASE ENZYME INHIBITORS; ANGIOGENESIS INHIBITORS; ANTITUMOR AND ANTIPROLIFERATIVE AGENTS GLAXO WELLCOME INC. 2002-02-26 US disclosed
EP-1165514-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2002-01-02 EP disclosed
WO-2000056710-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2000-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040191210-A1 Compounds CDK1, AKT1, RPS6KA1 TGM2 3487/4885PIM1 579/4885MAOA 2011/4885
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia PRKDC, PRKX, BMX TGM2 2251/4885PIM1 863/4885MAOA 2705/4885
US-20030069430-A1 Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects SRC, CDK2, CDK1 TGM2 2342/4885PIM1 1541/4885MAOA 3420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.